Register for our free email digests:
Division of PharmaMar SA
Latest From Orphagen Pharmaceuticals Inc.
Amgen’s July 31 deal with Japan’s Teijin marks at least the six partnerships around RORγt inhibitor compounds since 2009, with one more such deal likely this year. Plus news from a busy deal-making week, including tie-ups for AstraZeneca and Fibrogen, Actelion and Ceptaris, and Bristol and Samsung.
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Therapeutic Areas
- Grupo Zeltia
- Western Europe
- Parent & Subsidiaries
- PharmaMar SA
- Senior Management
- J.M. Fernandez Sousa, Pres.
- Contact Info
Phone: (34) 914 444 500
Plaza del Descubridor, Diego de Ordas 3
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.